HB-500 is a next-generation therapeutic vaccine being developed in collaboration with Gilead Sciences, Inc. (Gilead) as a potential component of a curative regimen for human immunodeficiency virus (HI ...

The COVID-19 pandemic forced investigators conducting clinical trials to use decentralized elements, such as telehealth, to ...

Alexander I. Spira, MD, PhD, FACP, discusses the clinical implications of ctDNA for treatment decisions and monitoring in ...

We recently published a list of 35 Non-Tech AI Opportunities Amid DeepSeek Selloff. In this article, we are going to take a ...

Inc. stock despite strong Phase 2b data. Click for my updated look at MNMD stock and its market opportunities.

ImmunityBio shares were up 14% to $3.52 after the company entered into a collaboration and supply agreement with BeiGene. The two companies will conduct a confirmatory randomized Phase 3 clinical ...

BioNTech SE (NASDAQ:BNTX), a biotechnology company renowned for its mRNA technology platform and COVID-19 vaccine success, is navigating a crucial phase in its evolution. With a market capitalization ...

The interim leader of the National Institutes of Health gave some clarification tied to Trump administrations restrictions on ...

The trial combines tislelizumab and Anktiva for treating advanced or metastatic non-small cell lung cancer patients. Credit: NMK-Studio/Shutterstock. ImmunityBio has entered a supply agreement and ...

Clinical trial agreements (CTAs) form the foundation of any clinical research initiative, establishing the legal and ...

Robert F. Kennedy Jr., President Donald Trump's pick to lead the top U.S. health agency, told U.S. senators during his ...